Squarepoint Ops LLC Sells 431,734 Shares of DENTSPLY SIRONA Inc. $XRAY

Key Points

• Squarepoint Ops LLC cut its DENTSPLY SIRONA stake by 88.6% in the second quarter, selling 431,734 shares and retaining 55,600 shares worth approximately $590,000.
• Analysts maintain a consensus “Hold” rating on XRAY, with an average price target of $13.31; ratings include three Buys, nine Holds, and three Sells.
• DENTSPLY SIRONA reported quarterly EPS of $0.52, beating estimates of $0.35, while revenue of $898 million exceeded expectations but declined 4.1% year over year. Shares opened at $9.54, near the company’s 52-week low of $9.36.

Squarepoint Ops LLC reduced its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 88.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,600 shares of the medical instruments supplier's stock after selling 431,734 shares during the period. Squarepoint Ops LLC's holdings in DENTSPLY SIRONA were worth $590,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Eurizon Capital SGR S.p.A. bought a new position in shares of DENTSPLY SIRONA in the 4th quarter valued at about $26,000. Nykredit A S bought a new position in DENTSPLY SIRONA in the second quarter valued at approximately $38,000. Performa Ltd US LLC grew its stake in DENTSPLY SIRONA by 116.1% in the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 2,283 shares in the last quarter. Allworth Financial LP acquired a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth approximately $51,000. Finally, Huntington National Bank raised its stake in shares of DENTSPLY SIRONA by 68.3% during the 4th quarter. Huntington National Bank now owns 4,689 shares of the medical instruments supplier's stock worth $54,000 after purchasing an additional 1,903 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on XRAY. Piper Sandler increased their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a "neutral" rating in a report on Wednesday, July 29th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Barclays increased their price target on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an "underweight" rating in a research note on Monday, August 24th. Barrington Research set a $15.00 price objective on shares of DENTSPLY SIRONA in a research report on Monday, August 10th. Finally, BMO Capital Markets lowered their price objective on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a "market perform" rating on the stock in a research note on Thursday. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $13.31.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $9.54 on Friday. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -3.47, a PEG ratio of 1.21 and a beta of 0.84. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63. The company has a 50-day simple moving average of $11.91 and a 200 day simple moving average of $11.49. DENTSPLY SIRONA Inc. has a 52 week low of $9.36 and a 52 week high of $14.76.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The firm had revenue of $898.00 million for the quarter, compared to analysts' expectations of $889.93 million. During the same period in the prior year, the firm earned $0.52 EPS. The business's revenue was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, sell-side analysts predict that DENTSPLY SIRONA Inc. will post 1.4 earnings per share for the current year.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental laboratories, and other oral health professionals with solutions spanning preventive, restorative, endodontic, orthodontic, implant, and prosthetic dentistry.

Its portfolio includes dental consumables, equipment and treatment centers, imaging systems, CAD/CAM systems, instruments, dental materials, implants, orthodontic products, and software and digital workflow solutions.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.